GlassScriptPhysician profile
Hugh A Burt
NPI 1972599371
$1,463.25
in general payments reported to CMS, 2019-2025
24 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $348 · 2021: $179 · 2022: $36.39 · 2024: $94.33 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $199.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $369.73 | 2019-2021 | |
| Medtronic Vascular, INC. | $167.58 | 2019 | |
| Mylan Specialty L.P. | $141.92 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.88 | 2021-2024 | |
| Amarin Pharma, INC. | $98.89 | 2019-2021 | |
| Novo Nordisk INC | $86.37 | 2021-2025 | Rybelsus, Ozempic |
| Topcon Healthcare Solutions, INC. | $62.40 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $54.96 | 2020 | |
| Glaxosmithkline, LLC. | $41.57 | 2019-2020 | |
| Allergan, INC. | $36.57 | 2019-2021 | |
| Lilly USA, LLC | $36.09 | 2020-2025 | Zepbound, Mounjaro |
| Vanda Pharmaceuticals INC. | $30.47 | 2019-2020 | |
| Forte Bio-Pharma LLC | $24.66 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.73 | 2019 | |
| Grt US Holding, INC. | $22.91 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.62 | 2025 | Repatha, Otezla |
| Boston Scientific Corporation | $20.59 | 2025 | General - Pain Management |
| Exact Sciences Corporation | $17.59 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.23 | 2021 | |
| Astellas Pharma US INC | $16.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.75 | 2021 | |
| Medtronic USA, INC. | $14.29 | 2019 | |
| Abbvie INC. | $13.48 | 2022 | |
| Pfizer INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugh Burt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.